Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 2 Pituitary Neoplasms 1 Pain 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Lung Neoplasms 1 Hemorrhage 1 Haloperidol 1 Growth Hormone-Secreting Pituitary Adenoma 1 Brain Neoplasms 1 Anemia 1 Acromegaly 1

Interventions

Paclitaxel 20 Gemcitabine 16 Dexamethasone 16 Bevacizumab 16 Docetaxel 15 Oxaliplatin 14 Cyclophosphamide 13 Carboplatin 12 Capecitabine 12 Sorafenib 11 Fluorouracil 11 Leucovorin 10 Cisplatin 10 pembrolizumab 9 Prednisone 9 Pemetrexed 9 Epoetin Alfa 9 venetoclax 8 atezolizumab 8 Fentanyl 8 Drug Therapy 8 Doxorubicin 8 Rivaroxaban 7 Rituximab 7 Darbepoetin alfa 7 Anastrozole 7 Panitumumab 6 Ondansetron 6 Morphine 6 Irinotecan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × Solutions × Clear all

NCT01836328 2016-03-16

RATIOMTD

L'Hospitalet de Llobregat

Phase 3 Completed

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡